← Leaderboards
Ramesh K Ganju
Beth Israel Deaconess Medical Center
$10,257,043
Attributed
$11,356,397
Total exposure
9
Grants
6
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $728.7K · FY2005–25$1M$750K$500K$250K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$11,356,397 · 9
By mechanism
R01$10,177,274 · 6
R21$784,232 · 2
R29$394,891 · 1
Top collaborators
- Bhuvaneswari Ramaswamy4 shared
- Daniel G. Stover1 shared
Most similar at Beth Israel Deaconess Medical Center
Same institution · by research overlap
- Raghu Kalluri$29,360,132
Others in their field
Top investigators on “Innovation”
- David R. Weir · University Of Michigan At Ann Arbor$382,307,654
- Eric Jeffrey Topol · Cleveland Clinic Lerner Col/Med-Cwru$319,874,172
- Margaret Juliana McElrath · Fred Hutchinson Cancer Center$311,654,401
- Richard A Gibbs · Baylor College Of Medicine$300,634,418
- Gerald T Nepom · Benaroya Research Inst At Virginia Mason$298,740,071
- Judith S. Currier · University Of California Los Angeles$271,752,220
Research focus
InnovationMediatingPathway InteractionsSignal TransductionMolecularMouse ModelPlayMalignant Breast NeoplasmIn VivoNeoplasm MetastasisKnockout MiceLeadBiological ModelsIn VitroProteinsTumorTriple-Negative Invasive Breast CarcinomaInsightBinding (Molecular Function)CellsTumor ProgressionGrowthTissuesMortality Vital Statistics
Grant awards (42)
Unravel the novel role of S100A7 and its functional partners in Metastatic Triple Negative Breast Cancer Racial Disparity$469,544
R01 · FY2025 · CA · contact PI
Unravel the novel role of S100A7 and its functional partners in Metastatic Triple Negative Breast Cancer Racial Disparity$469,544
R01 · FY2024 · CA · contact PI
Addressing cancer disparity through defining the molecular link between breast feeding and triple negative breast cancer$437,753
R01 · FY2023 · CA
Addressing cancer disparity through defining the molecular link between breast feeding and triple negative breast cancer$434,990
R01 · FY2022 · CA
Addressing cancer disparity through defining the molecular link between breast feeding and triple negative breast cancer$443,868
R01 · FY2021 · CA
Addressing cancer disparity through defining the molecular link between breast feeding and triple negative breast cancer$441,049
R01 · FY2020 · CA
Addressing cancer disparity through defining the molecular link between breast feeding and triple negative breast cancer$441,049
R01 · FY2019 · CA
Role of Slit in CXCR4-mediated breast cancer metastasis$168,999
R01 · FY2019 · CA · contact PI
Role of Slit in CXCR4-mediated breast cancer metastasis$248,621
R01 · FY2018 · CA · contact PI
Role of Slit in CXCR4-mediated breast cancer metastasis$242,550
R01 · FY2017 · CA · contact PI
Role of Slit in CXCR4-mediated breast cancer metastasis$248,621
R01 · FY2016 · CA · contact PI
Role of Slit in CXCR4-mediated breast cancer metastasis$248,621
R01 · FY2015 · CA · contact PI
Role of S100A7 in breast cancer progression and metastasis$291,940
R01 · FY2014 · CA · contact PI
Role of Slit in CXCR4-mediated breast cancer metastasis$242,550
R01 · FY2014 · CA · contact PI
Role of S100A7 in breast cancer progression and metastasis$62,369
R01 · FY2014 · CA · contact PI
Role of S100A7 in breast cancer progression and metastasis$9,089
R01 · FY2014 · CA · contact PI
Role of S100A7 in breast cancer progression and metastasis$282,912
R01 · FY2013 · CA · contact PI
Role of S100A7 in breast cancer progression and metastasis$300,969
R01 · FY2012 · CA · contact PI
Novel approaches to attenuate lipopolysaccharide-induced inflammation$190,625
R21 · FY2012 · AI · contact PI
Synthetic cannabinoids as novel therapeutic strategies against non-small cell lun$165,844
R21 · FY2012 · CA · contact PI
Role of S100A7 in breast cancer progression and metastasis$300,969
R01 · FY2011 · CA · contact PI
Novel approaches to attenuate lipopolysaccharide-induced inflammation$228,750
R21 · FY2011 · AI · contact PI
Synthetic cannabinoids as novel therapeutic strategies against non-small cell lun$199,013
R21 · FY2011 · CA · contact PI
Role of Chemokine & T-Cell Receptors in HIV Pathogenesis$500,613
R01 · FY2009 · HL · contact PI
Role of Slit in CXCR4-Mediated Breast Cancer Metastasis$224,720
R01 · FY2009 · CA · contact PI
Role of Chemokine & T-Cell Receptors in HIV Pathogenesis$375,000
R01 · FY2008 · HL · contact PI
Role of Slit in CXCR4-Mediated Breast Cancer Metastasis$211,532
R01 · FY2008 · CA · contact PI
Role of Chemokine & T-Cell Receptors in HIV Pathogenesis$215,946
R01 · FY2007 · HL · contact PI
Role of Chemokine & T-Cell Receptors in HIV Pathogenesis$180,261
R01 · FY2007 · HL · contact PI
Role of Slit in CXCR4-Mediated Breast Cancer Metastasis$155,770
R01 · FY2007 · CA · contact PI
Role of Slit in CXCR4-Mediated Breast Cancer Metastasis$98,912
R01 · FY2007 · CA · contact PI
Role of Chemokine & T-Cell Receptors in HIV Pathogenesis$425,000
R01 · FY2006 · HL · contact PI
Role of Slit in CXCR4-Mediated Breast Cancer Metastasis$262,288
R01 · FY2006 · CA · contact PI
HIV-1 gp120 Mediated Chemotaxis of Blood Cells$297,500
R01 · FY2005 · AI
Role of Slit in CXCR4-Mediated Breast Cancer Metastasis$268,600
R01 · FY2005 · CA
HIV-1 gp120 Mediated Chemotaxis of Blood Cells$297,500
R01 · FY2004 · AI
HIV-1 gp120 Mediated Chemotaxis of Blood Cells$297,500
R01 · FY2003 · AI
HIV-1 gp120 Mediated Chemotaxis of Blood Cells$297,500
R01 · FY2002 · AI
CHARACTERIZATION SIGNAL TRANSDUCTION IN KAPOSIS SARCOMA$136,827
R29 · FY2002 · CA
HIV-1 gp120 Mediated Chemotaxis of Blood Cells$282,625
R01 · FY2001 · AI
CHARACTERIZATION SIGNAL TRANSDUCTION IN KAPOSIS SARCOMA$131,563
R29 · FY2001 · CA
CHARACTERIZATION SIGNAL TRANSDUCTION IN KAPOSIS SARCOMA$126,501
R29 · FY2000 · CA